OncologyOnline.net

Oncology Xagena

The LUME-Lung 1 trial has demonstrated a significant overall survival advantage for Nintedanib ( Vargatef ) plus Docetaxel ( Taxotere ) compared with placebo plus Docetaxel as second-line therapy for ...


Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung 3 and LUX-Lung 6, in patients with EGFR-mutant advanced non ...


Basal cell carcinomas are the most common skin cancers. They are usually localised and carry a good prognosis. There is no standard treatment for the rare patients with metastatic basal cell carcinoma ...


The efficacy and safety of Dabigatran ( Pradaxa ) for treatment of venous thromboembolism ( VTE ) were demonstrated in two trials. It is unclear if the results pertain to patients with cancer and veno ...


The FDA ( Food and Drug Administration ) has granted Priority Review for the New Drug Application ( NDA ) for Cobimetinib in combination with Vemurafenib ( Zelboraf ) for the treatment of people with ...


The FDA ( Food and Drug Administration ) has expanded the approved use of Opdivo ( Nivolumab ) to treat patients with advanced ( metastatic ) squamous non-small cell lung cancer ( NSCLC ) with progres ...


LUX-Lung 1 was a phase IIb/III study that looked at the benefit of Afatinib ( Giotrif ) and best supportive care in comparison with placebo and best supportive care, as a third-line or fourth-line the ...


The efficacy of the ALK inhibitor, Crizotinib ( Xalkori ) as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer ( NSCLC ) is unknown. A ...


Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. A phase II trial has assessed the antitumor acti ...


Prolonging first-line chemotherapy results with maintenance treatment may influence overall survival. In HER2-negative patients with locally recurrent/metastatic breast cancer, combining Bevacizumab ( ...


Nivolumab ( Opdivo ) is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity. A phase II trial assessed the antitumor activity ...


The anti-programmed-death-receptor-1 ( PD-1 ) antibody Pembrolizumab ( Keytruda ) has shown potent antitumour activity at different doses and schedules in patients with melanoma. Researchers have co ...


The Food and Drug Administration ( FDA ) approved Akynzeo for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but ...


Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced urothelial cancer ( also known as bladder cancer ) presented at ESMO ( European Society f ...


Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced gastric cancer were presented during the ESMO ( European Society for Medical Oncology ) 2 ...


Data from the coBRIM phase III study were presented at ESMO ( European Society of Medical Oncology ) 2014 Congress. The results have shown that people with previously untreated BRAF V600 mutation-po ...


The results from CheckMate -037, a phase 3 randomized, controlled open-label study of Nivolumab ( Opdivo ), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemothera ...


The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and ...


Treatment outcomes for older patients with acute myeloid leukemia ( AML ) have remained dismal. A randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy comp ...


Combining Bevacizumab ( Avastin ) with first- or second-line chemotherapy in randomised phase III trials showed significantly improved progression-free survival in HER2-negative locally recurrent / me ...


The combination of stent insertion and single high-dose brachytherapy is a feasible and safe palliative treatment regimen in patients with unresectable oesophageal cancer. A study has assessed the e ...


Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. However, how best to minimise the time spent taking cytotoxic drugs and whether molecular selection ...


The prevention of medullary thyroid cancer in patients with multiple endocrine neoplasia ( MEN ) type 2 syndrome has demonstrated the ability of molecular diagnosis and prophylactic surgery to improve ...


Bevacizumab ( Avastin ), a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. A study has assessed the role of Bevacizumab as adjuvant treatment ...


In the treatment of metastatic colorectal cancer, inferior overall survival, progression-free survival, and objective response rates have been shown in people with RAS mutations ( at exons 2, 3, and 4 ...


Ipilimumab ( Yervoy ) is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. A study has assessed the use of Ipilimumab after radiotherapy i ...


Bone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride ( Radium-223 ) selectively targets bone metastases with high-en ...


An established multivariate serum protein test can be used to classify patients according to whether they are likely to have a good or poor outcome after treatment with EGFR tyrosine-kinase inhibitors ...


In the treatment of metastatic colorectal cancer, inferior overall survival, progression-free survival, and objective response rates have been shown in people with RAS mutations ( at exons 2, 3, and 4 ...


Current guidelines recommend both epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors ( TKIs ) and cytotoxic chemotherapy drugs as standard treatment options for patients with wild-ty ...


The combination of stent insertion and single high-dose brachytherapy is a feasible and safe palliative treatment regimen in patients with unresectable oesophageal cancer. A study has assessed the ...


Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of Oxaliplatin ( Eloxatin ) and Fluorouracil ( ...


Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. Resear ...


Bisphosphonates are routinely used in the treatment of metastatic bone disease from breast cancer to reduce pain and bone destruction. Zoledronic acid ( Zometa ) given by intravenous infusion has been ...


Inflammation is an important feature of the malignant phenotype and promotes angiogenesis, tumour invasiveness, metastases, and cachexia. Researchers used a first-in-class, monoclonal antibody ( MAB ...


In the randomised, controlled, phase 3 trial NeOAdjuvant Herceptin ( NOAH ) trial in women with HER2-positive locally advanced or inflammatory breast cancer, neoadjuvant Trastuzumab ( Herceptin ) has ...


Bevacizumab ( Avastin ), a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. A study has assessed the role of Bevacizumab as adjuvant treatment ...


Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of Oxaliplatin ( Eloxatin ) and Fluorouracil ch ...


The androgen receptor inhibitor Enzalutamide ( Xtandi ) is approved for the treatment of metastatic castration-resistant prostate cancer that has progressed on Docetaxel. A study has assessed the ac ...


The anti-EGFR monoclonal antibodies Panitumumab ( Vectibix ) and Cetuximab ( Erbitux ) are effective in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer. A st ...


Four cycles of Etoposide ( Vepedis ) plus Cisplatin ( Platinol ) and accelerated hyperfractionated thoracic radiotherapy ( AHTRT ) is the standard of care for limited-stage small-cell lung cancer ( SC ...


Definitive chemoradiotherapy is a curative treatment option for oesophageal carcinoma, especially in patients unsuitable for surgery. The PRODIGE5/ACCORD17 trial aimed to assess the efficacy and saf ...


An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor therapies. Fibroblast growth factor ( FGF ) pathway activation ha ...


Patients with advanced cancer have reduced quality of life, which tends to worsen towards the end of life. Researchers have assessed the effect of early palliative care in patients with advanced cance ...


Afatinib ( Giotrif ) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LUX-Lung 3 ( LL3 ) has compared Afatinib with Cisplatin / Pemetrexed in 345 patients recrui ...


Improved disease control with continuation of EGFR inhibition beyond progression has been suggested in retrospective / non-randomized studies, however, this has yet to be prospectively evaluated in a ...


Pembrolizumab ( MK-3475 ) has demonstrated antitumor activity and acceptable safety in a phase I melanoma cohort. Researchers have provided updated efficacy data and correlation with tumor PD-L1 exp ...


Erlotinib ( Tarceva ) is FDA-approved for the first-line treatment of EGFR mutant non-small cell lung cancer ( NSCLC ), with a median progression free survival ( PFS ) of 10.4 months. Nivolumab, a f ...


Antiangiogenic agents Sunitinib ( Sutent ) and Pazopanib ( Votrient ) are SOC ( standard of care ) for metastatic renal cell carcinoma ( mRCC ), but new therapies are needed as patients advance throug ...


A phase 2 multicenter, randomized, open-label, study has evaluated the safety and efficacy of Pidilizumab ( CT-011 ), a humanized anti-PD-1 IgG1k, in patients with metastatic melanoma. Eligibility ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati